The Role of Community Pharmacists in Drug Information Services in Lamongan During the COVID-19 Pandemic
Abstract
Information about drugs has spread widely across social media platforms during the COVID-19 pandemic, resulting in drug panic buying. However, public awareness and understanding about how to use drugs properly remains low. This phenomenon may lead to medication errors. Community pharmacists can provide information about the rational use of drugs though a differential diagnosis approach by comparing clinical symptoms of similar minor illnesses to increase patient safety in taking medication. This research aimed to investigate drug information services and the ideal components of counselling, information, and education (KIE) carried out by community pharmacists in drugstores during the COVID-19 pandemic. This was observational research conducted in 12 drugstores in Lamongan from April 2021 to July 2021. The data were gathered by checklists of 8 criteria of ideal KIE based on pharmacy service standards in the drugstores. The results indicated that there was an appropriate adjustment in providing drug information during the COVID-19 pandemic. Appropriate pharmacist activity in giving KIE was 68.6%, patient response to drug information services was 61.6%, and patient ability to repeat the information was 64.9%. The pharmacists are expected to have comprehensive knowledge and ability to provide drug information services. Also, they should be more communicative to increase awareness, willingness, and ability to promote a healthy life during the pandemic.
Keywords: community pharmacy, drug information, COVID-19
References
[1] WHO, “WHO Coronavirus (COVID-19) Dashboard.,”
[2] C.T. Owens and R. Baergen, “Pharmacy Practice in High-Volume Community Settings: Barriers and Ethical Responsibilities.,” MDPI. vol. 9, no. 2, p. 74, 2021.
[3] M. Nasir, A.S.M.S. Chowdhury, and T. Zahan, “Self-medication during COVID-19 outbreak: a cross sectional online survey in Dhaka city.,” International Journal of Basic & Clinical Pharmacology. vol. 9, no. 9, p. 1325, 2020.
[4] A. Hossain, M. Raknuzzaman, and M. Tokumura, “Coronavirus (COVID-19) Pandemic: Concern about Misuse of Antibiotics.,” Journal of Biomedical Analytics. vol. 3, no. 2, pp. 19–23, 2020.
[5] C.E. Oldenburg, B.A. Pinsky, J. Brogdon, et al., “Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients with SARS-CoV-2 Infection: A Randomized Clinical Trial.,” JAMA - Journal of the American Medical Association. vol. 326, no. 6, pp. 490–498, 2021.
[6] C.D. Spinner, R.L. Gottlieb, G.J. Criner, et al., “Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial.,” JAMA - Journal of the American Medical Association. vol. 324, no. 11, pp. 1048–1057, 2020.
[7] P.R. Utami, S. Sholikhah, A.K. Putri, D.R. Octavia, and E. Rahmawati, “Pharmacists ’ Efforts in Community Pharmacy to Achieve Health Protocol Compliance During the Covid- 19 Pandemic in Lamongan,.” Strada. vol. 10, no. 1, pp. 310–317, 2021.
[8] S. Ghaibi, H. Ipema, and M. Gabay, ASHP guidelines on the pharmacist’s role in providing drug information., 2015.
[9] M. Alomar, “Community Pharmacy Prescription Screening in the UAE.,” Pharmacology & Pharmacy. vol. 05, no. 01, pp. 83–91, 2014.
[10] WHO, Guideline on GPP:Standards for quality of pharmacy services., 2011.
[11] pmk no.73, “Permenkes RI No.73 tahun 2016,” (2016).
[12] C.E. Eades, J.S. Ferguson, and R.E. O’Carroll, “Public health in community pharmacy: A systematic review of pharmacist and consumer views.,” BMC Public Health. vol. 11, p. 2011.
[13] GPhC, “Standards for pharmacy professionals.,” In: General Pharmaceutical Council Canada. pp. 4–6 (2017).
[14] F.T. Arenatha, “Analisis Pelayanan Kefarmasian Pengobatan Swamedikasi Diukur Dari Penerapan Pendekatan Diagnosis Diferensial Dan 8 Kriteria Kie Ideal.,” Jurnal Ilmiah Mahasiswa Universitas Surabaya. vol. 3, no. 1, pp. 1–19, 2014.
[15] A.E.L. Nurjannah, H. Lilfitriyani, and A. Basith, “EVALUASI PELAYANAN KOMUNIKASI, INFORMASI, DAN EDUKASI (KIE) TENAGA KEFARAMASIAAN YANG ADA DI KABUPATEN BOJONEGORO.,” JURNAL PENJAS DAN FARMASI. vol. 3, pp. 15–20, 2020.
[16] R. Ciliberti, N.L. Bragazzi, and A. Bonsignore, “The Implementation of the Professional Role of the Community Pharmacist in the Immunization Practices in Italy to Counteract Vaccine Hesitancy.,” Pharmacy (Basel, Switzerland). vol. 8, no. 3, p. 2020.
[17] J.C. Hayden and R. Parkin, “The challenges of COVID-19 for community pharmacists and opportunities for the future.,” Irish journal of psychological medicine. vol. 37, no. 3, pp. 198–203, 2020.
[18] T.H. Mallhi, A. Liaqat, A. Abid, et al., “Multilevel Engagements of Pharmacists During the COVID-19 Pandemic: The Way Forward.,” Frontiers in public health. vol. 8, p. 561924, 2020.
[19] A.A. Jairoun, S.S. Al-Hemyari, M. Shahwan, et al., “A Quantitative Evaluation of Evidence-Based Beliefs and Implementation Among Community Pharmacists: Findings and Impact from United Arab Emirates.,” Risk management and healthcare policy. vol. 14, pp. 967–977, 2021.
[20] D.R. Octavia, M.S. Zakaria, and D. Nurafifah, “Tingkat Pengetahuan Masyarakat Tentang Swamedikasi yang Rasional di Lamongan.,” Surya. vol. 11, no. 02, pp. 10–16, 2019.
[21] D.P. Sari, “Evaluasi Penggunaan Obat Rasional di Puskesmas Kabupaten Pasuruan Tahun 2019 Berdasarkan Indikator Pencapaian Kementerian Kesehatan.,” FARMASIS: Jurnal Sains Farmasi. vol. 1, no. 1, pp. 1–5, 2020.
[22] D.R. Octavia, I. Susanti, S. Bintang, et al., “PENINGKATAN PENGETAHUAN MASYARAKAT TENTANG PENGGUNAAN DAN PENGELOLAAN OBAT YANG RASIONAL MELALUI PENYULUHAN DAGUSIBU.,” GEMASSIKA. vol. 4, no. 1, pp. 23– 39, 2020.
[23] Y. Liao, C. Ma, A.H. Lau, and M. Zhong, “Role of pharmacists during the COVID-19 pandemic in China - Shanghai Experiences.,” Journal of the American College of Clinical Pharmacy : JACCP. p. 2020.
[24] Kusuma S; and T. Sandi, Komunikasi Pasien Dengan Farmasi (Konseling Farmasi). , Jakarta, 2012.
[25] N.R. Mahesti and A. Susilowati, “Description of Compliance Level of Antihypertensive Drug Use At.,” AKFARINDO. vol. 4, no. 1, pp. 15–19, 2019.
[26] S. Watanabe, “[Drug information for safe use].,” Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol. 134, no. 3, pp. 351–353, 2014.
[27] H. Wali, Z. Hudani, S. Wali, K. Mercer, and K. Grindrod, “A systematic review of interventions to improve medication information for low health literate populations.,” Research in social & administrative pharmacy : RSAP. vol. 12, no. 6, pp. 830–864, 2016.